Copenhagen, Denmark, March 14, 2017
Wolfgang Amann, former Head of Sobi's commercial operations in the German Speaking European Countries, to Take Helm.
Angusta now available for all women requiring induction of labour in the Nordic Countries.
Azanta A/S ("Azanta"), a specialty pharma company with a focus
on medical treatments in women¹s health, oncology and addiction
medicine with operations in Copenhagen, Denmark and the rest of the
Nordic Countries, announced today that it has appointed Wolfgang
Amann to serve as its Chief Executive Officer (CEO).
The appointment of Wolfgang Amann as CEO takes place simultaneously with the Company's market launch of Angusta in the five Nordic countries.
Angusta is a new and best medicine for labour induction. Azanta has developed Angusta over several years, and the regulatory dossier for Angusta was submitted in early 2016 for regulatory approval in the five Nordic countries. In February 2017 Azanta was informed by the relevant medicine agencies that regulatory approval would be granted. Angusta will be launched in the Nordics in April 2017 making Angusta available for all women requiring induction of labour in these countries.
"Wolfgang brings a strong commercial background and experience in the pharmaceutical industry to Azanta", said David Kauffmann, Chairman of the Azanta Board of Directors and Managing Founding Partner of EEP. "Wolfgang has been responsible for several successful product launches in Europe and with the upcoming commercial launch of Angusta, our recently approved medicine for labour induction, Wolfgang has the ideal background for taking Azanta to the next level as a leader in selected niche markets within women's health".
Wolfgang Amann has been working in the pharmaceutical industry for more than 20 years, having been responsible for sales and operations as country manager for pharma companies. Most lately, Wolfgang was responsible for SOBI's commercial activities in the European German speaking countries. Prior to SOBI, Wolfgang was Country Manager in Austria for Mitsubishi Pharma.
"Joining the Azanta Executive team at this important time in the Company's lifecycle is a great privilege," said Wolfgang Amann. "The Company has, despite a very challenging situation in recent years, been successful in securing approval of Angusta and maintaining solid operations and market presence with its other products. Today, Azanta has a great opportunity to realise strong growth over time with the market launch of Angusta in the Nordics and the planned approval of Angusta in other countries".
"With the successful approval of Angusta and the fact that Azanta is becoming much more commercially oriented, I concur that time has come to appoint a CEO with a strong commercial profile", said Hanne Damgaard Jensen, who is leaving the role as CEO of Azanta. Hanne has been the leader of Azanta's drug development activities for Nimoral and Angusta since inception of the product ideas. She has a successful background in drug development and has also been the driving force behind the regulatory approval of Angusta. Hanne Damgaard Jensen has been leading the daily effort of getting Azanta back on track since she was appointed CEO in April 2015. Azanta's Board of Directors would like to take the opportunity to thank Hanne for her great performance in a very challenging period and not least for having successfully lead the development and regulatory approval of Angusta.
Azanta (www.azanta.com) is a privately-owned specialty pharma company with a focus on medical treatments in women´s health, oncology and addiction medicine. Azanta seeks to be an international market leader within certain specialty pharma product categories, particularly in niche women's health and orphan oncology indications, employing innovative repositioning and drug formulation strategies. Azanta currently sells in-licensed and its own medical products in the Nordic countries and has pipeline of products in late stage development.
For additional information contact David Kauffmann, Chairman, firstname.lastname@example.org, +41 79 585 92 51.